menu
    • menu
    [{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Ivacaftor","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Cystic Fibrosis Foundation","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"Cystic Fibrosis Foundation \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cystic Fibrosis Foundation \/ Royalty Pharma"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Calithera Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Beyond Air","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Nitric Oxide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"inhalation","sponsorNew":"Cystic Fibrosis Foundation \/ CF Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Cystic Fibrosis Foundation \/ CF Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Microbion","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cystic Fibrosis Foundation","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"inhalation","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"5","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Cystic Fibrosis Foundation","amount2":0.11,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Pulmocide","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Opelconazole","moa":"CYP51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension For Inhalation","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"BiomX","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"BX004","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Cystic Fibrosis Foundation","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Peptilogics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"PLG0301","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Aridis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Gallium Citrate","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cystic Fibrosis Foundation","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Aerosol","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Anagram Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Enzyme-based Therapy","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cystic Fibrosis Foundation","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"ARCT-032","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Cystic Fibrosis Foundation","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Aerosol (PMDI)","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Prime Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cystic Fibrosis Foundation","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"ReCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Gene Correction Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Cystic Fibrosis Foundation","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Cystic Fibrosis Foundation \/ Cystic Fibrosis Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by Cystic Fibrosis Foundation

    Menu

    Cystic Fibrosis Foundation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gene Correction Therapy

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : ReCode Therapeutics

                            Deal Size : $15.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ReCode Receives Cystic Fibrosis Foundation Funding for Gene Correction Therapies

                            Details : The proceeds will be used to accelerate ReCode’s gene correction research program with the goal of developing and commercializing new treatments for people with cystic fibrosis.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 18, 2024

                            Lead Product(s) : Gene Correction Therapy

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : ReCode Therapeutics

                            Deal Size : $15.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : Prime Medicine

                            Deal Size : $15.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation

                            Details : The net proceeds will be used to support the development of curative therapies by using Prime Editing to correct CFTR mutations at the natural genetic locus, for the treatment of Cystic Fibrosis (CF).

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 25, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : Prime Medicine

                            Deal Size : $15.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARCT-032

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Recipient : Arcturus Therapeutics

                            Deal Size : $25.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational ...

                            Details : The funding will advance ARCT-032, a novel messenger RNA (mRNA) therapeutic candidate formulated with Arcturus’ LUNAR® delivery technology for the treatment of Cystic Fibrosis.

                            Brand Name : ARCT-032

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 26, 2023

                            Lead Product(s) : ARCT-032

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Recipient : Arcturus Therapeutics

                            Deal Size : $25.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enzyme-based Therapy

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : Anagram Therapeutics

                            Deal Size : $15.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Cystic Fibrosis Foundation Commits Up to $15.5M in Additional Funding for Potential Enzyme Therapy

                            Details : If the therapy is successful, people with CF would be able to decrease the number of enzyme pills they must take to digest food properly from a handful of pills to only one per meal.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 04, 2023

                            Lead Product(s) : Enzyme-based Therapy

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : Anagram Therapeutics

                            Deal Size : $15.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gallium Citrate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Recipient : Aridis Pharmaceuticals

                            Deal Size : $12.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CF Foundation Invests Up to $4.85 Million in Aridis Pharmaceuticals for Testing of Anti-Infective

                            Details : AR-501 is a novel, small molecule and an inhalable form of gallium citrate, which acts as an iron analog to starve bacteria of iron. Gallium is believed to inhibit multiple iron-dependent synthetic and metabolic pathways required for pathogenicity.

                            Brand Name : AR-501

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 12, 2022

                            Lead Product(s) : Gallium Citrate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Aridis Pharmaceuticals

                            Deal Size : $12.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BX004

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : BiomX

                            Deal Size : $5.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CFF Supporting Phase 1/2 Trial of Phage Therapy for P. aeruginosa Infections

                            Details : BiomX has been given grant to support a clinical trial of BX004, a phage therapy to fight Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). In lab experiments conducted by BiomX, BX004 killed antibiotic-resistant strains of P. aerugi...

                            Brand Name : BX004

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 05, 2022

                            Lead Product(s) : BX004

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : BiomX

                            Deal Size : $5.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PLG0301

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Peptilogics

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential...

                            Details : The award provided by the Cystic Fibrosis Foundation will generate both in vitro and in vivo data about PLG0301 and PLG0206, which may potentially support an Investigational New Drug (IND) application with the FDA for its continued development.

                            Brand Name : PLG0301

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            January 05, 2022

                            Lead Product(s) : PLG0301

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Peptilogics

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Pulmocide

                            Deal Size : $3.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CF Foundation Invests $3.5 Million in Pulmocide for Development of Novel Antifungal Treatment for Lung Transpl...

                            Details : The CF Foundation’s funding will support Phase 2 study of opelconazole. The objective of the study is to assess the safety and tolerability and patient’s ability to complete the course of treatment when used to prevent invasive pulmonary fungal infec...

                            Brand Name : PC945

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 06, 2021

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Pulmocide

                            Deal Size : $3.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery

                            Recipient : Flagship Pioneering

                            Deal Size : $110.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Pioneering Medicines, an Initiative of Flagship Pioneering, Establishes First-of-its-Kind Partnership with Cys...

                            Details : Pioneering Medicines and the Cystic Fibrosis Foundation will partner with multiple companies within the Flagship ecosystem, leveraging emerging technologies including Tessera Therapeutics’ Gene WritingTM technology, targeted delivery modalities, and RN...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 03, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery

                            Recipient : Flagship Pioneering

                            Deal Size : $110.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cystic Fibrosis Foundation

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pravibismane

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Recipient : Microbion

                            Deal Size : $7.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Microbion Corporation Receives Additional Funding Support from the Cystic Fibrosis Foundation to Speed Advance...

                            Details : This new funding of up to $1.8 million will directly support IND-enabling toxicology studies of pravibismane and is in addition to $5.6 million previously awarded by the Foundation, for a combined total of up to $7.4 million.

                            Brand Name : MBN-101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 22, 2021

                            Lead Product(s) : Pravibismane

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Recipient : Microbion

                            Deal Size : $7.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth